News

2021 AGM CEO’s Speech
23 Nov 2021
Today I will provide you with an update on the launch of NEXTSTELLIS our novel contraceptive which received FDA approval earlier this year together with some comments around our evolving specialty products business model and our outlook.
Learn more

Mayne Pharma provides FDA update on generic NUVARING®
7 Oct 2021
Mayne Pharma Group Limited (ASX: MYX) has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) in relation to its abbreviated new drug application (ANDA) for a generic version of NUVARING.
Learn more

Mayne Pharma appoints new Director
4 Oct 2021
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Carolyn Myers, M.B.A., Ph.D. has accepted an invitation to join the Board of Mayne Pharma Group Limited, effective immediately
Learn more

Generic ABSORICA® added to US portfolio
29 Sep 2021
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has begun distribution of isotretinoin capsules, 10 mg, 20 mg, 30 mg and 40 mg in the United States.
Learn more

FDA Approves Lexette® for Adolescent Plaque Psoriasis
22 Sep 2021
Mayne Pharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved LEXETTE® (halobetasol propionate) foam, 0.05% for use in adolescents.
Learn more

2021 Full Year Results Media Release
27 Aug 2021
2021 Full Year Results Media Release
Learn more

Mayne Pharma Board Renewal and New Chairman
26 Aug 2021
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Mr Frank Condella, a US resident, will be appointed Chairman with effect from 30 September 2021.
Learn more

Class action proceeding
3 Aug 2021
Mayne Pharma Group Limited (ASX: MYX) has been served with a class action proceeding against Mayne Pharma in the Supreme Court of Victoria.
Learn more

Mayne Pharma expands Australian dermatology portfolio
21 Jun 2021
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has licensed the Australian rights to SOLARAZE®
Learn more